Jun 09 (Japan Times) - A Japanese unit of British drugmaker AstraZeneca said Thursday that it has applied for approval from the health ministry to manufacture and sell its COVID-19 prevention and treatment drug in Japan.
AstraZeneca K.K., the Osaka-based unit, is seeking fast-track approval for the AZD7442 drug, known abroad as Evusheld.
The drug is expected to be administered to people who cannot receive existing COVID-19 vaccines due preexisting conditions, among other factors.
Source: 日テレNEWS